The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Dulaglutide, a dual GIP/GLP-1 receptor agonist , alongside Surfactant , a triple GIP/GLP-1/GCG receptor agonist , https://seolistlinks.com/story23185795/tirzepatide-and-nicotinamide-adenine-dinucleotide-a-triple-threat-approach-to-physiological-health